Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Wright Reports
Provider: GlobalData
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Veloxis Pharmaceuticals A/S' Final STRATO Clinical Study Data Demonstrates Potential For LCP-Tacro to Improve Tacrolimus-Induced Tremors

Monday, 20 May 2013 02:30am EDT 

Veloxis Pharmaceuticals A/S announced that data from the STRATO study demonstrates potential for LCP-Tacro to improve tacrolimus-induced tremors in stable kidney transplant patients. The study, Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO) clinical trial, was presented at the 13th American Transplant Congress, Abstract B1022, on May 19, 2013 in Seattle. In this open-label trial, 44 kidney transplant patients who were stable on twice-daily tacrolimus and had a complaint of hand tremor were switched to once-daily LCP-Tacro. Tremor was evaluated by independent neurologists using a validated rating scale (the FTM scale) and by an objective measurement of tremor frequency and amplitude by Tremorometer. In addition, the patients and the clinicians separately assessed global sense of improvement following the switch to LCP-TacroTM. Both the patient- and physician-reported global assessments demonstrated significant overall improvements following the switch to LCP-Tacro (p<0.001). Most patients in the study are continuing on a long-term extension phase of the study, receiving LCP-Tacro. Two other Veloxis-sponsored abstracts will be presented at the conference. 

Company Quote

-0.01 -1.12%
5 Mar 2012